DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Onasemnogene abeparvovec
Onasemnogene abeparvovec
Spotlight on Market Access Actionable Understandings from AIS Health’S In-Depth Coverage
Curriculum Vitae
Immunoprophylaxis of Influenza Using AAV Vector Delivery of Cross
Innovationsreport 2020 Kurzfassung
Zolgensma, INN-Onasemnogene Abeparvovec
Med Pharm PA List to Build Pdfs.Xlsx
Virtual Posters
Pharmacotherapy of Spinal Muscular Atrophy (SMA), 5.01.574
Aetna PA Info
Issue Brief. Gene Therapy in 2019: Milestones and Challenges
Pre-Certification Requirements for Procedures, Programs & Drugs
MSM CH 1200 Draft 06-29-21
Measured Moments
(INN) for Biological and Biotechnological Substances
Prior Authorization List
Serve You Rx Prior Authorization Information and Drug List
Horizon Scanning Status Report June 2020 Prepared For: Patient-Centered Outcomes Research Institute 1828 L St., NW, Suite 900 Washington, DC 20036
Zolgensma® (Onasemnogene Abeparvovec-Xioi)
Top View
High Potential Disruption Report May 2020
Emerging Therapies Workgroup (June 18, 2019)
Download a Caregiver's Guide To
Zolgensma, INN-Onasemnogene Abeparvovec
Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): an Updated Review
For Spinal Muscular Atrophy (SMA)
Advanced Therapy Medicinal Products
ZOLGENSMA Safely and Effectively
Services and Medicare Part B Drugs These Services May Or May Not Be Covered by Your Healthpartners Plan
2020 Medicaid Preapproval Criteria
Zolgensma® (Onasemnogene Abeparvovec-Xioi)
Prior Authorization List* for Blue Shield and FEP Members Effective July 1, 2021
New Drugs & Biologics
(Zolgensma®) “Notification”
Department of Health Care Services
Novel Treatments for Orphan Diseases: a Promising Future September 20Th, 2019
Overview of Gene Therapy in Spinal Muscular Atrophy and Duchenne
Zolgensma (Onasemnogene Abeparvovec)
A View Into Upcoming Specialty & Traditional Drugs
Zolgensma (Onasemnogene Abeparvovec): Risk for Thrombotic Microangiopathy
Zolgensma (Onasemnogene Abeparvovec) Gene Therapy for Treatment of Spinal Muscular Atrophy (SMA) Type I Effective: April 21, 2021
Authorizations for Medical Drugs
Risk Assessment and Risk Mitigation Review(S)
Services and Medicare Part B Drugs These Services May Or May Not Be Covered by Your Healthpartners Plan
Committee for Advanced Therapies (CAT). Minutes of the Meeting 19
New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
Onasemnogene Abeparvovec-Xioi)
2020 Medicines in Development for Children
For Spinal Muscular Atrophy
Zolgensma® (Onasemnogene Abeparvovec-Xioi) – Oxford Clinical
EVRYSDI™ (Risdiplam) Oral
(CAT). Agenda for the Meetting on 11-13 September 2019
First Quarter, 2020 Coding Cycle for Drug and Biological Products
05/01/2021 – Unitedhealthcare Value & Balance Exchange Medical
RNA-Targeted Therapies and High-Throughput Screening Methods
Outcomes in Patients with Spinal Muscular Atrophy Given Nusinersen
Optimizations of in Vitro Mucus and Cell Culture Models to Better Predict in Vivo Gene Transfer in Pathological Lung Respiratory
ACTA MYOLOGICA (Myopathies, Cardiomyopathies and Neuromyopathies)